Navigation Links
Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant awarded to Johns Hopkins Early Career investigator
Date:1/19/2010

PHILADELPHIA The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Zeshaan A. Rasheed, M.D., Ph.D., the 2010 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant. This grant, totaling $600,000 over five years, will support Rasheed's efforts to examine the relevance of cancer stem cells in pancreatic adenocarcinoma.

Cancer stem cells are a subset of cells hypothesized to mediate the growth and spread of cancer.

"This is a critical area of research that will lay the groundwork for new therapies that can effectively treat pancreatic cancer and stem the tide of this devastating, and too frequently fatal, disease," said Margaret Foti, Ph.D., M.D. (h.c.), CEO of the American Association for Cancer Research. "We are pleased to partner with the Pancreatic Cancer Action Network in order to distribute this and other grants that underscore the urgency to fund high quality, impactful research leading to breakthroughs that save lives."

"This is the first year that we have offered the Pathway to Leadership Grant," stated Julie Fleshman, J.D., M.B.A., president and CEO of the Pancreatic Cancer Action Network. "It is a highly competitive award that was developed to attract the brightest and most promising early-career scientists to the field of pancreatic cancer to ensure future leadership of the research community. We congratulate Dr. Rasheed on receiving this esteemed award and we look forward to working with him."

Rasheed earned his medical degree and doctorate in cellular and molecular pharmacology from the University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School and Graduate School of Biomedical Sciences. Currently, he is a medical oncology fellow at The Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins, Johns Hopkins University School of Medicine. His funded research focuses on how different populations of pancreatic cancer stem cells are related to one another and which factors regulate cancer stem cell growth and spread throughout the body. By making these determinations, Rasheed will then investigate how cancer stem cell inhibition is possible, which may lead to the development of novel cancer stem cell-targeting therapies.

The newly introduced Pathway to Leadership Grant is open to postdoctoral or clinical research fellows. It parallels the highly coveted K99/R00 early-career investigator awards that are offered by the National Cancer Institute. Recipients receive financial support for two years of mentored research followed by three years of independent research. Funding decisions for the Pathway to Leadership Grant are made by an outside committee of experts in pancreatic cancer using a rigorous and transparent process. Importantly, in addition to receiving research funds, grant recipients are provided with career development opportunities. These include mentorships and connections with senior scientists; invitations to present at scientific sessions, lead conference workshops and participate in training and educational webinars; site visits to mentor laboratories to learn new techniques and skills; involvement with pancreatic cancer survivors and their caregivers; and information resources to keep them apprised of emerging developments in the field.

The grant will be formally awarded at the AACR Annual Meeting on April 20, 2010. The term for the grant begins on July 1, 2010.

In its mission to accelerate pancreatic cancer research, the Pancreatic Cancer Action Network collaborated with AACR to promote and support outstanding research focused on conquering this deadly disease. Nine grants through four grant mechanisms will be awarded in 2010, with a total funding level of nearly $2.3 million. This represents the largest annual dollar amount disbursed since the Pancreatic Cancer Action Network introduced the program in 2003. It reflects nearly a 90 percent increase in funding since last year.

The goals of the grants program are to emphasize the urgent need to expedite scientific and medical breakthroughs that benefit patients, build a cadre of researchers dedicated to the field of pancreatic cancer research and encourage collaboration, information-sharing and innovation.


'/>"/>

Contact: Michele Leiberman
michele.leiberman@aacr.org
267-646-0622
American Association for Cancer Research
Source:Eurekalert  

Related biology news :

1. Obesity and lack of exercise could enhance the risk of pancreatic cancer
2. Low levels of key protein may indicate pancreatic cancer risk
3. Birth records hold pancreatic cancer clue
4. Naturally-occurring apple compounds reduce risk of pancreatic cancer
5. Elusive pancreatic stem cells found in adult mice
6. Mesothelin engineered on virus-like particles provides treatment clues for pancreatic cancer
7. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
8. UC Davis researchers discover Achilles heel in pancreatic cancer
9. Researchers engineer pancreatic cell transplants to evade immune response
10. DNA repair patterns may predict risk of pancreatic cancer
11. U-M researchers ID gene involved in pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant awarded to Johns Hopkins Early Career investigator
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: